Oruka Therapeutics, Inc. ORKA Increase in accrued expenses and other liabilities
Increase in accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s increase in accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s increase in accrued expenses and other liabilities?
- Oruka Therapeutics, Inc. (ORKA) reported increase in accrued expenses and other liabilities of -$1.3M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s increase in accrued expenses and other liabilities changed year-over-year?
- Oruka Therapeutics, Inc.'s increase in accrued expenses and other liabilities decreased by 156.3% year-over-year, from $2.32M to -$1.3M.
- What is the long-term trend for Oruka Therapeutics, Inc.'s increase in accrued expenses and other liabilities?
- Over 2 years (2022 to 2024), Oruka Therapeutics, Inc.'s increase in accrued expenses and other liabilities has grown at a 161.7% compound annual growth rate (CAGR), from -$934K to $6.4M.
- What does increase in accrued expenses and other liabilities mean?
- Reflects the net change in expenses that have been incurred but not yet paid, such as accrued compensation or professional fees. An increase typically indicates a deferral of cash outflows, while a decrease suggests the settlement of these obligations.